Please login to the form below

Not currently logged in
Email:
Password:

Novartis’ heart failure drug approved via early access scheme

LCZ696 issued positive scientific opinion under EAMS
Novartis Building

Novartis' heart failure medicine LCZ696 has become the first non-oncology treatment to be accepted under the UK's Early Access to Medicine Scheme (EAMS).

The new treatment will therefore be available to eligible patients in the NHS before European regulators officially approve it.

EAMS was launched last year with the hope of giving patients with life-threatening conditions access to medications that are not yet currently approved.

The Medicines and Healthcare products Regulatory Agency (MHRA), which oversees EAMS, issued a positive scientific opinion based on trial data that showed LCZ696 (sacubitril valsartan) was more effective than the current gold standard of treatment.

The phase III trial, known as Paradigm-HF, pitted LCZ696, an angiotensin receptor neprilysin inhibitor (ARNi), against Merck's ACE-inhibitor enalapril.

The findings showed that patients treated with LCZ696 were 20% less likely to die from a cardiovascular cause or hospitalisation and were also 16% less likely to die from any cause.

Novartis had previously estimated peak sales for LCZ696 at $5bn, however some analysts have concluded it could reach $10bn - further warranting its description by Novartis CEO Joe Jimenez as a 'multi-blockbuster'.

Hugh O'Dowd, general manager at Novartis UK & Ireland, said: “Despite widespread use of available treatments and implementation of NICE guidelines, outcomes remain poor for those diagnosed with heart failure. So it's very encouraging that LCZ696 will be available via the EAMS, allowing patients in the UK with this debilitating condition to gain benefit.

“We are working closely with the NHS to ensure eligible patients have rapid access under the scheme while we await the final European licensing decision.”

Heart failure affects around 550,000 people in the UK and costs the NHS roughly £2.3bn a year. Prognosis is still poor, however, as around 60% of patients diagnosed with heart-failure die within five years.

Article by
Nikhil Patel

3rd September 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics